| __timestamp | Apellis Pharmaceuticals, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 22570000 |
| Thursday, January 1, 2015 | 6356782 | 24378000 |
| Friday, January 1, 2016 | 4303743 | 26621000 |
| Sunday, January 1, 2017 | 10463151 | 28653000 |
| Monday, January 1, 2018 | 22639184 | 37734000 |
| Tuesday, January 1, 2019 | 67046483 | 41884000 |
| Wednesday, January 1, 2020 | 139401000 | 64435000 |
| Friday, January 1, 2021 | 176771000 | 57483000 |
| Saturday, January 1, 2022 | 277163000 | 70062000 |
| Sunday, January 1, 2023 | 500815000 | 52790000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Apellis Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have shown contrasting trends in their SG&A expenditures. From 2014 to 2023, Apellis saw a staggering increase of over 17,000% in their SG&A expenses, peaking at approximately $500 million in 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Ligand Pharmaceuticals maintained a more stable trajectory, with expenses fluctuating modestly around $50 million to $70 million annually. This stability suggests a more conservative approach, focusing on steady growth and cost management. As the pharmaceutical landscape evolves, these financial strategies highlight the diverse paths companies take to achieve success.
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Exelixis, Inc. vs Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Opthea Limited and Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Agios Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?